Journal of Clinical Endocrinology & Metabolism, Vol 79, 384-389, Copyright © 1994 by Endocrine Society

ARTICLES

Expression of thyrotropin receptor and thyroid hormone receptor messenger ribonucleic acid in normal, hyperplastic, and neoplastic human thyroid tissue

M Bronnegard, O Torring, J Boos, C Sylven, C Marcus and G Wallin
Department of Pediatrics, Karolinska Institute, Stockholm, Sweden.

In the first part of this study, we examined TSH receptor (TSHR) and thyroid hormone receptor (T3R beta) messenger ribonucleic acid (mRNA) levels in normal, hyperplastic, and neoplastic human thyroid tissue. Tumor specimens from patients with different thyroid carcinomas and thyroid adenomas, and tissues from patients with Graves' disease and from normal thyroid glands were analyzed by solution hybridization and Northern blot using complementary RNA probes. In the second part of the study, mRNA analysis of T3R was extended to include the expression levels of each of the four T3R isoforms alpha 1, alpha 2, beta 1, and beta 2. In neoplastic thyroid tissue such as papillary and follicular carcinomas, the expression of both TSHR and T3R beta mRNA per microgram total RNA was significantly lower than that in normal thyroid tissue. The decrease in T3R beta mRNA was shown to represent a specific and significant decrease in T3R beta 2 mRNA levels in particular, but also in the expression levels of T3R beta 1 mRNA. No differences were found in the expression levels of T3R alpha 1 or -alpha 2 mRNA. Furthermore, no differences in TSHR or T3R mRNA levels were found in thyroid tissue from patients with Graves' disease compared to normal thyroid tissue. It is concluded that the reduction of TSHR and T3R mRNA in specific neoplastic thyroid tissues might be associated with the differentiation state of these tumors and that the decrease in T3R mRNA levels is due to a specific decrease in the expression levels of the T3R beta gene.

This article has been cited by other articles:

				B. Joseph, M. Ji, D. Liu, P. Hou, and M. Xing Lack of Mutations in the Thyroid Hormone Receptor (TR) {alpha} and Genes but Frequent Hypermethylation of the TR Gene in Differentiated Thyroid Tumors J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4766 - 4770. [Abstract] [Full Text] [PDF]

				K. Moriyama, T. Tagami, T. Usui, M. Naruse, T. Nambu, Y. Hataya, N. Kanamoto, Y.-s. Li, A. Yasoda, H. Arai, et al. Antithyroid Drugs Inhibit Thyroid Hormone Receptor-Mediated Transcription J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1066 - 1072. [Abstract] [Full Text] [PDF]

				A. S. Rocha, R. Marques, I. Bento, R. Soares, J. Magalhaes, I. V. de Castro, and P. Soares Thyroid hormone receptor {beta} mutations in the 'hot-spot region' are rare events in thyroid carcinomas J. Endocrinol., January 1, 2007; 192(1): 83 - 86. [Abstract] [Full Text] [PDF]

				M. Xing, H. Usadel, Y. Cohen, Y. Tokumaru, Z. Guo, W. B. Westra, B. C. Tong, G. Tallini, R. Udelsman, J. A. Califano, et al. Methylation of the Thyroid-stimulating Hormone Receptor Gene in Epithelial Thyroid Tumors: A Marker of Malignancy and a Cause of Gene Silencing Cancer Res., May 1, 2003; 63(9): 2316 - 2321. [Abstract] [Full Text] [PDF]

				M. Puzianowska-Kuznicka, A. Krystyniak, A. Madej, S.-Y. Cheng, and J. Nauman Functionally Impaired TR Mutants Are Present in Thyroid Papillary Cancer J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1120 - 1128. [Abstract] [Full Text] [PDF]

				N. J. L. Gittoes, C. J. McCabe, J. Verhaeg, M. C. Sheppard, and J. A. Franklyn Thyroid Hormone and Estrogen Receptor Expression in Normal Pituitary and Nonfunctioning Tumors of the Anterior Pituitary J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1960 - 1967. [Abstract] [Full Text] [PDF]